Kesimpta
ofatumumab
Multiple Sclerosis, Relapsing-Remitting
Date of authorisation:
Revision: 8
Last updated:
MedicineHumanAuthorised
EMEA-002397-PIP01-18-M03 - paediatric investigation plan
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Neurology
PIP number: P/0537/2022
Route(s) of administration: Subcutaneous use
Pharmaceutical form(s):
Solution for injection
Decision date:
Last updated:
Compliance check: ✖
PIPHuman
Dzuveo
sufentanil
Pain
Date of authorisation:
Revision: 6
Last updated:
MedicineHumanAuthorised
Zalviso
sufentanil
Pain, Postoperative
Date of authorisation:
Revision: 7
Last updated:
MedicineHumanWithdrawn
Arzerra
ofatumumab
Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation:
Revision: 16
Last updated:
MedicineHumanWithdrawn